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ORIGINAL ARTICLE
Use of capsule endoscopy in the emergency department as a triage
of patients with GI bleeding
Joseph J. Y. Sung, MD, PhD, Raymond S. Y. Tang, MD, Jessica Y. L. Ching, MPH, Timothy H. Rainer, MD,
James Y. W. Lau, MD
Hong Kong
Background and Aims: Upper GI bleeding (UGIB) still constitutes one of the major hospital admissions
through emergency departments (EDs). This feasibility study aims to test whether capsule endoscopy (CE)
can reduce unnecessary hospital admissions in patients with suspected UGIB.
Methods: This was a prospective randomized controlled trial in which patients who presented with symptoms or
signs suggestive of UGIB were randomized to receive either the standard treatment (ST) of hospital management
or receive CE, after which hospital admission was determined by the ﬁndings of CE. Patients were also graded by
Glasgow Blatchford score (GBS) at the ED for assessment of need of hospital admission.
Results: Seventy-one patients fulﬁlled the recruitment criteria, with 37 subjects enrolled into the CE group and
34 subjects into the ST group. Seven CE patients with active bleeding or signiﬁcant endoscopic ﬁndings were
admitted to the hospital compared with the ST group in which all 34 patients were admitted. There was no dif-
ference in the clinical outcome in terms of recurrent bleeding and 30-day mortality. Hospital admission was also
greatly reduced if CE instead of GBS was used to triage patients in the ED.
Conclusions: This feasibility study shows that CE offers a safe and effective method in triaging patients present-
ing with symptoms of UGIB that do not require hospital admission. (Clinical trial registration number:
NCT02446678.) (Gastrointest Endosc 2016;-:1-7.)
Patients coming to the hospital with “coffee ground”
vomiting or “tarry stools” may not actually have active
upper GI bleeding (UGIB). Hospital admission can be
avoided if active UGIB or high-risk lesions are excluded
in the emergency department (ED). To date, the only use-
ful tool to triage patients for hospital admission with UGIB
is by using a clinical score such as the Rockall score1 or
Glasgow Blatchford score (GBS),2 but these scoring
systems can only exclude the most benign cases. In a
large cohort study using the GBS, 22% of patients who
were seen with UGIB were considered low risk and
could be managed as outpatients.3 Subsequent studies
show that most patients with suspected UGIB are still
admitted to the hospital unnecessarily.4 The number of
patients who can avoid early endoscopy is only modest.5
Capsule endoscopy (CE) can be used to identify
patients with fresh blood and “coffee ground” substance
in the stomach and is superior to nasogastric tubes for
this purpose. In a previous cohort study, we reported
that CE detected 9 cases of fresh blood or “coffee grounds”
in the duodenum, whereas nasogastric tube aspirate was
reported to be bilious or clear in 7 of these 9 cases.6 We
concluded that in an ED setting, CE is feasible and safe
in patients presenting with acute UGIB. CE may facilitate
patient triage and earlier endoscopy. It was also
suggested that Pillcam ESO (Given Imaging Ltd.,
Yoqneam, Israel) is more accurate than a clinical scoring
system in risk stratiﬁcation of patients presenting to the
ED with acute UGIB.7
The objective of the current study is to validate CE as an
effective tool in diagnosing patients with UGIB and identi-
fying those who require hospital admission. It is our aim
to study whether CE can reduce unnecessary hospital
Abbreviations: CE, capsule endoscopy; ED, emergency department; GBS,
Glasgow Blatchford score; ST, standard treatment; UGIB, upper GI
bleeding.
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admissions in patients with suspected UGIB. We also
aim to compare the effectiveness of CE against the GBS
in identifying patients with UGIB who may require early
endoscopic intervention.
METHODS
This prospective randomized controlled trial was
approved by the university hospital clinical research ethics
committee and registered at the Clinical Trial Registry
(NCT02446678). Written informed consent was obtained
from patients whomet inclusion criteria before study enroll-
ment. Patientswhowere recruited into this studyhad to be at
least 18 years of age or older. They presented to the ED of
hospitals with symptoms of acute overt UGIB, namely “cof-
fee ground” vomiting and/or melena. Exclusion criteria
included (1) those who had hemodynamic shock (systolic
blood pressure below 90 mm Hg and pulse rate over 120/
min); (2) those who presented with fresh hematemesis;
(3) those who had dysphagia, odynophagia, swallowing dis-
order, and/or Zenker’s diverticulum; (4) those who had con-
ditions that might contraindicate the use of CE (eg,
suspected bowel obstruction and/or perforation, Crohn’s
disease, previous GI surgery); (5) those who had altered
mental status; (6) pregnant and/or lactating women; and
(7) those with a known history of esophageal varices or
gastric variceswithorwithout prior bleedinghistory. Patients
who had upper or lower GI malignancy were also excluded.
Before randomization, 10 mL of blood was taken from
patients for a complete blood count, coagulation proﬁle,
renal tests, and liver function tests. Other demographic
data and parameters for GBS calculation were also collected.
The primary outcome was the number of patients
requiring hospital admission, and the secondary outcomes
included safety, clinical rebleeding, and mortality.
Comparing the effectiveness of CE against the GBS in iden-
tifying patients with UGIB who may require endoscopic
intervention was also a secondary outcome of this study.
Eligible patients were randomized to receive either CE
or standard-of-care treatment (ST). Based on the current
standard practice of the hospital, patients presenting with
clinical or biochemical evidence of UGIB were admitted
to the hospital for monitoring and early endoscopic evalu-
ation (hence included in the ST group). On the other
hand, patients who were not conﬁrmed to have UGIB
symptoms, who had stable hemodynamic measurements,
and who showed no drop in hemoglobin levels were
Clinical parameters including
routine blood counts, vital signs monitoring
Patient present to Emergency Room
with symptoms suggestive of UGIB
Capsule group (CE)
Ingestion of PillCam
No evidence of
UGIB
With evidence 
of UGIB
Monitoring BP
Pulse for 6 h
stable BP & pulse for at least 6 hours
Discharge home
& FU by EGD
within 3 days
BP<90 or Pulse >120
for at least 2 h
                          Standard group (ST)
Admit to hospital and carry out standard of care
Endoscopy within 24 hours
of admission
Eligibility criteria assessment
and consent process
Figure 1. Study ﬂow diagram. BP, blood pressure; FU, follow-up.
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discharged from the ED. All patients in the ST group were
admitted to the hospital by ED physicians within 24 hours.
Endoscopic examination of the upper GI tract was offered
to all patients within 24 hours, and hemostasis therapy was
applied as necessary (Fig. 1).
In the CE group, hospital admission was determined
by the ﬁndings of CE. After conﬁrming that the patient
had fasted for at least 5 hours, patients in the CE group
ingested the PillCam ESO 2 using the simpliﬁed ingestion
procedure. Thirty to 60 minutes before capsule ingestion,
each patient received a single dose of intravenous metoclo-
pramide 10 mg, which helped to promote gastric motility
and improved visualization of the gastric mucosa at endos-
copy. Upper GI tract images (esophagus to the second
portion of the duodenum) were obtained in real time
at the patient’s bedside. The video images that were
transmitted by the PillCam ESO 2 were displayed in real
time on the tablet computer screen (REAL time viewer,
Given Imaging Ltd., Yoqneam, Israel). A full-length CE
video recording was obtained for subsequent capsule
workstation downloading and complete review.
The CE videos received a 2-tier review: initial bedside
real-time review by trained research personnel for obvious
fresh blood, blood clots, or “coffee ground” material, fol-
lowed by a formal review after completion of the CE by a
staff gastroenterologist with extensive experience in CEs
of the small bowel, colon, and esophagus. Both research
personnel and the gastroenterologist underwent a 2-day
capsule training program organized by Given Imaging Ltd
and received accreditation after the training.
A formal CE report was produced within 2 hours after
capsule ingestion. The ﬁnding of fresh blood or “coffee
Capsule Group
         N=37
Standard Group
           N=34
             Total GIB
(Nov 2013 - Nov 2014)
              (N=1167)
Excluded cases
-Hemetemesis: n=159
-Known EV/GV: n=2
-Active cancer: n=50
-PRB: n=181
-PR exam with no melena: n=
277
-GI Surgery done: n=8
-Refused study: n=23
-*Non-accessible cases:
n=274
-#Others: n=122
Recruited
 subjects
    N=71
Evaluable cases
          n=34
Evaluable cases
          n=34
Admission
      N=7
Admission
      N=34
Discharged
   from ER
      n=27
 Home after
hospital stay
      n=7
 Home after
hospital stay
      n=34
Non evaluable
cases:
-1 known history
of variceal
bleeding
- 1 fever that
precluded early
endoscopy
-1 capsule did not 
pass out of
esophagus before
battery run out
* Non-accessible cases: holiday, out of screening time, unable to be contacted,
discharged home at ED directly, warded or EGD directly
# Others: on feeding tube, unable to understand consent, EGD arranged before study
assessment 
Figure 2. Randomization of subjects into the 2 treatment groups: capsule endoscopy (CE) or standard treatment (ST). EV, esophageal varices; GV, gastric
varices; PRB, per rectal bleeding; PR, per rectal; ED, emergency department.
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grounds” was documented. Upper GI pathologies that
might lead to bleeding were also recorded. Patients in
the CE group were admitted to the hospital based on sig-
niﬁcant ﬁndings deﬁned as either evidence of signiﬁcant
bleeding or ﬁndings of serious GI lesions by CE that might
be related to UGIB. Evidence of signiﬁcant bleeding
included (1) ﬁnding of more than 5 mL “coffee ground”
material (by estimation) in the upper GI tract, (2) ﬁnding
of fresh blood in the stomach without active bleeding,
or (3) ﬁnding of fresh blood in the stomach with active
bleeding from an identiﬁable upper GI lesion. Serious
endoscopic ﬁndings included (1) peptic ulcer showing
Forrest I/II stigmata, (2) esophageal or gastric varices, or
(3) malignancy of the stomach or esophagus. Patients
who had no sign of active bleeding, showed no serious
endoscopic ﬁndings, and had stable blood pressure and
heart rate for at least 6 hours were discharged from the ED.
All admitted patients in the CE group underwent EGD
within 24 hours after completion of CE. Discharged CE
patients were scheduled to have an outpatient EGD within
3 days after discharge. Findings of the EGD were recorded,
and corresponding treatment was delivered according to
standard practice. All patients were followed up by phone
call on day 30 to assess the recurrent bleeding episode.
Sample size calculation
Based on the assumption that all patients in the ST
group were admitted to the hospital, CE can reduce hospi-
tal admission by 30% (ie, from 100% to 70%). To achieve an
alpha of .05 and beta of .1, the study needed no fewer than
34 patients in each treatment group. Hence, a minimum of
68 patients were required.
Statistical analysis
Descriptive statistics of demographic data, CE ﬁndings,
conventional endoscopy ﬁndings, clinical rebleeding, and
mortality are presented. The 95% conﬁdence interval (CI)
for single proportion was calculated as described by the
Wilson method.
RESULTS
Seventy-one patients fulﬁlled the recruitment criteria,
with 37 subjects enrolled into the CE group and 34 subjects
into the ST group. Three subjects in the CE group were sub-
sequently excluded after identifying a history of variceal
bleeding in one and fever after admission that precluded
early endoscopy in another (both had no CE done). One
patient, after swallowing the capsule, refused to ingest 15
mL of water per 30 seconds until the capsule entered into
the stomach. The capsule did not pass out of the esophagus
before the battery ran out. However, the capsule was
excreted smoothly on the same day without causing any
adverse events. Therefore, data for 34 patients in each treat-
ment groupwere analyzed (Fig. 2). Age, sex, baseline systolic
and diastolic blood pressure, pulse rate, initial hemoglobin
levels, serum urea level, prothrombin time, and
international normalized ratio were comparable (Table 1).
Seven patients in the CE group were considered to have
evidence of bleeding or signiﬁcant clinical ﬁndings. This
included “coffee ground” material in 2 (5.9%), peptic ulcer
with Forrest Ib stigmata in 2 (5.9%), Forrest IIa in 2 (5.9%),
and esophageal varix in 1 (3%). No evidence of bleeding or
signiﬁcant endoscopic ﬁndings were reported in 27 of 34
patients (79.4%). Subsequently, conventional endoscopy
in this group revealed 11 peptic ulcers (including 5 gastric
ulcers, 4 duodenal ulcers, and 2 with both gastric and
duodenal ulcers), 1 esophageal varix, 7 gastritis/duodenitis,
5 gastric/duodenal erosions, and 1 case of gastrointestinal
stromal tumor (GIST). There was no malignancy reported
in this group (Table 2). In the ST group, endoscopy
ﬁndings included peptic ulcers in 14 (2 gastric ulcers
[GU] and 12 duodenal ulcers [DU]), gastritis/duodenitis
in 10, gastric or duodenal erosions in 5, and Mallory
Weiss tear in 1. No varix or malignancy was found
(Table 3). Assuming the 3 patients randomized to the CE
group who were excluded (1 with known history of
variceal bleeding, 1 with fever, and 1 with failed CE
examination) were admitted to the hospital, the number
of patients admitted was 10 of 37. The discharged-from-
ED rate decreased from 79.4% (27/34) to 73.0% (27/37).
Seven patients in the CE group with active bleeding
or signiﬁcant endoscopic ﬁndings were admitted to the
hospital after initial assessment in the ED. Three (42.9%;
95% CI, 15.8%-75.0%) were subsequently conﬁrmed
to have high-risk lesions (1 esophageal varix, 1
TABLE 1. Patient demographics
CE group
(n [ 34)
ST group
(n [ 34)
Male 21 (61.8) 24 (70. 6)
Age (mean  SD), y 55.2  18.7 54.9  21.71
Baseline (mean  SD)
Systolic blood pressure 132.4  21.0 133.7  24.4
Diastolic blood pressure 78.4  8.8 72.9  12.6
Pulse 85.2  17.5 83.8  16.3
Hemoglobin 12.8  1.6 11.7  2.7
Urea 7.0  3.4 8.3  4.8
Prothrombin time 10.5  1.8 11.8  4.0
INR 1.0  .07 1.1  .4
Presenting symptoms
“Coffee ground” vomiting 10 (29.4) 5 (14.7)
Melena 22 (64.7) 29 (85.3)
Both CG and melena 2 (5.9) 0 (0)
Values are number of cases with percents in parentheses, unless otherwise noted.
CE, Capsule endoscopy; ST, standard treatment; SD, standard deviation;
INR, international normalized ratio; CG, “coffee ground” vomiting.
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gastrointestinal stromal tumor (GIST) with coffee ground,
and 1 gastric ulcer with fresh blood) (Table 2). All were
treated by endoscopy, with no recurrent bleeding within
30 days of follow-up. Among the 27 patients in the CE
group showing no evidence of signiﬁcant bleeding by
CE who were sent home, 1 patient (3.7%; 95% CI,
.7%-18.3%) was subsequently found to have a gastric ulcer
with a visible vessel. His case was uneventful in the 3-day
follow-up until endoscopy found the gastric ulcer. None
of these 27 cases developed clinical bleeding at home
requiring admission. All 34 patients in the ST group were
admitted. Five (14.7%) were found to have Forrest I/II
peptic ulcers and 1 (2.9%) had a Mallory Weiss tear with
a visible vessel (17.6%; 95% CI, 8.3%-33.5%) (Table 3).
Patients were treated by a standard endoscopic method,
and none had recurrent bleeding within the 30-day
follow-up. There was no mortality in both the CE and ST
groups in this study.
The average attendance time for the CE group was
6 hours and for the ST group, 2.5 hours. The CE procedure
was done by 2 endoscopy nurse specialists. After swallow-
ing, patients were observed for 10 minutes to monitor
capsule entry into the stomach. Once the capsule entered
the stomach, no close observation was needed at bedside.
The video was then downloaded for the physician’s review-
ing. The capsule videos were reviewed by a physician
within 15 minutes after completion of video data
downloading.
Based on the GBS of the patients undergoing CE while
in the ED, 6 patients scored 0 and 3 scored 1. In the ST
group, none scored 0 and 7 patients scored 1. Therefore,
if we adopt the admission criteria of admitting any patient
with a GBS over 1 (ie, 2 or above), 25 patients (73.5%; 95%
CI, 56.9%-85.4%) in the CE group and 27 patients (79.4%;
95% CI, 63.2%-89.7%) in the ST group required hospital
admission (Table 4). Applying CE in the 2 groups
obviated hospital admission by 16 of 68 and reduced the
admission rate by 76.5%.
DISCUSSION
A recent study has shown that in emergency CE in
patients with acute severe GI bleeding, even upper endos-
copy failed to detect the source of bleeding.8 This is the
ﬁrst randomized study to show that CE can be used
safely to identify which patients presenting with
symptoms suggestive of UGIB are high-risk individuals
TABLE 2. Endoscopy findings in the CE group
Capsule findings EGD findings
No evidence of significant bleeding 27* 30
Evidence of bleeding
>5 mL “coffee ground” material in stomach 2 1 (GIST)
Fresh blood in stomach but no active bleeding 0 0
Fresh blood and evidence of active bleeding 0 0
Endoscopic findings
Peptic ulcer Forrest I/II 4 (11.8%)
(2 oozing þ 2 v.v.)
2
(1 GU with fresh blood þ 1* GU with v.v.)
Peptic ulcer Forrest III 0 9 (3 GU, 4 DU, 2 GUþDU)
EV or GV (with or without SRH) 1 (EV) 1 (EV)
Malignancy of stomach or esophagus 0 0
CE, Capsule endoscopy; EGD, esophagogastroduodenoscopy; GIST, gastrointestinal stromal tumor; v.v., visible vessel; GU, gastric ulcer; DU, duodenal ulcer; EV, esophageal
varices; GV, gastric varices; SRH, stigmata of recent hemorrhage.
*One GU with visible vessel was missed by CE.
TABLE 3. Endoscopy findings in the ST group
EGD findings
Decisions
Admitted 34
Early discharge 0
Endoscopy findings
Esophageal ulcer 2
GU/DU 14 (5* DU)
GV/EV 0
Gastritis/duodenitis 10
Gastric/duodenal erosions 5
“Coffee grounds” only 0
Normal 1
Other 2 (1* MWT with v.v.)
Discharge outcome
Recurrent bleeding within 30 days 0
Mortality within 30 days 0
ST, Standard treatment; EGD, esophagogastroduodenoscopy; GU, gastric ulcer; DU,
duodenal ulcer; GV, gastric varices; EV, esophageal varices; v.v., visible vessel.
*Denotes significant bleeding.
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requiring hospital admission. It is safe in the sense that
swallowing the capsule endoscope in these patients did
not create any problems or adverse events. In the single
patient who failed to follow protocol (and hence the
capsule did not enter the stomach before the battery ran
out), the capsule passed within 1 day, causing no adverse
events. Moreover, CE also accurately identiﬁed esophageal
varices, most of the Forrest I or II peptic ulcers, and a case
of gastrointestinal stromal tumor (GIST) that produced
“coffee ground” vomiting. One case of Forrest II gastric
ulcer was missed by CE. With the use of CE, this study
showed that triaging patients can be done effectively
because hospital admission has been reduced by almost
80%. This is a large reduction in hospital work, which
carries a signiﬁcant impact on the ﬁnancial and workload
burden of the hospital system. This result, however, is
related to the emergency setting. Gastroscopy and colo-
noscopy are still needed during follow-up to discover the
source of bleeding.
We have to point out that this triage algorithmdid not use
CE alone; other clinical judgment was applied. Patients with
obvious signs of massive UGIB should be admitted to the
hospital without going through the capsule test. Therefore,
all patients who had hemodynamic shock (systolic blood
pressure below 90 mm Hg and pulse rate over 120/min)
and those who presented with fresh hematemesis were
excluded from the study because they obviously required
hospital admission. In fact, in this study 159 patients were
admitted because of hematemesis (Fig. 2). On the other
hand, if we used the conventional criteria in which all
patients presenting with hematemesis and/or melena
were admitted indiscriminately, most patients who did not
actually require hospitalization and urgent endoscopy
would have been admitted. Therefore, CE does not
preclude clinical discretion, and common sense still applies.
The GBS is among the most validated and popular
clinical scoring systems used to triage patients who require
hospital-based intervention. Recent studies have shown
that a GBS  1 or 2 can effectively identify patients with
low-risk UGIB, and hence those patients can be managed
on an outpatient basis.9,10 In prospective observational
studies, only 11% to 14% of patients were found to have
a GBS score equal to zero and considered safe to send
home.3,4 When GBS is used as a triage tool, hospital admis-
sion can be reduced by 15% to 20%.9 On the other hand,
high GBS at admission is associated with a high risk
of recurrent bleeding from the upper GI tract after
hospitalization.11
A previous small-scale nonrandomized study showed
that pre-endoscopy GBS and Rockall scores were inferior
to CE in differentiating high-risk from low-risk patients
with acute UGIB.10 In the current study in which patients
were randomized to receive either CE or ST, when
comparing the results of CE with the GBS, the former
can exclude more low-risk patients for unnecessary admis-
sion. Applying the GBS to the CE group, only 26.4% of
patients had a score of 1 or below (a similar percentage
of patients randomized to the ST group had a score of
1 or below). According to our previous study, 75% of
patients will be admitted to the hospital. However, only
7 of 34 cases were admitted to the hospital using CE as
the triage tool, reducing hospital admission by nearly
80%. As long as the patients could be contacted and
recalled for upper endoscopy, this triage method appears
to be quite safe because none of the patients recruited
had recurrent bleeding or died in the 30-day follow-up
period. This current study suggests that using when CE,
especially in communities where hospital beds are limited
and/or expensive, UGIB can be managed efﬁciently,
reducing hospital workload.
This study was designed to test whether applying CE
in the ED can reduce hospital admissions. In the control
arm of ST, all patients with strong clinical or biochemical
evidence of UGIB were admitted, and conventional endos-
copy was arranged. One might argue that a more relevant
comparison would be CE at ED against early upper endos-
copy and early discharge from ED. In many centers, early
endoscopy can only be done after the patient has been
admitted to the hospital. Endoscopy in the setting of the
ED is not widely available. Furthermore, in some centers,
even after hospital admission, endoscopy cannot be
arranged over holidays and weekends, and hence hospital-
ization is prolonged. The result of this study may therefore
suggest an alternative approach that could minimize
unnecessary hospital admission and shorten the waiting
time for endoscopic examinations.
There are several limitations to this study. This is a
small-scale study with only 34 subjects randomized to
each group. With a larger sample size, would there be
TABLE 4. GBS of patients in the CE and ST groups
GBS
Overall CE group ST group
n % n % n %
0 6 8.8 6 17.6 0 0.0
1 10 14.7 3 8.8 7 20.6
2 10 14.7 6 17.6 4 11.8
3 6 8.8 2 5.9 4 11.8
4 5 7.4 3 8.8 2 5.9
5 7 10.3 4 11.8 3 8.8
6 3 4.4 1 2.9 2 5.9
7 4 5.9 4 11.8 0 .0
8 8 11.8 4 11.8 4 11.8
9 1 1.5 0 .0 1 2.9
10 2 2.9 1 2.9 1 2.9
11 4 5.9 0 .0 4 11.8
12 1 1.5 0 .0 1 2.9
16 1 1.5 0 .0 1 2.9
CE, Capsule endoscopy; ST, standard treatment; GBS, Glasgow Blatchford score.
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cases of serious UGIB missed by CE and sent home, inad-
vertently leading to disastrous consequences? We cannot
rule out this possibility. The sample size was based on
the assumption that all patients in the ST group were
admitted to the hospital and CE could reduce hospital
admission by 30% (ie, from 100% to 70%). A large-scale
study should be considered to prove the efﬁcacy and safety
of this protocol.
One could also argue that the cost of CE is relatively
high or even prohibitive to be used for such screening
purposes. Compared with hospital admission and early
endoscopy, we are not sure which is more cost-effective.
This could be answered by conducting a cost-
effectiveness analysis using the local cost of hospital fees,
endoscopy charges, and various cost structures. The only
study available in the literature addressing the cost-
effectiveness analysis of CE compared with other strategies
to manage acute UGIB favors the use of CE in low- and
moderate-risk patients.12 This model was constructed
primarily based on a healthcare system in Western
developed countries. If the cost of CE falls, as it would
when technology further matures and market
competition increases, the use of CE as a triage tool may
become more cost-effective.
Finally, the use of CE requires training and expertise
so signiﬁcant lesions are not missed. Would this be
possible in a busy hospital ED? One needs to realize that
in this scenario, capsules are used primarily to detect fresh
blood and a signiﬁcant amount of “coffee ground” material.
Other important lesions that lead to major bleeding such
as large gastric or duodenal ulcers, varices, and upper GI
cancer are relatively easy to ﬁnd. The training of ED doc-
tors, or even endoscopy nurses, for this is feasible. Howev-
er, the capsule images should subsequently be examined
by endoscopists experienced in upper endoscopy and
CE to avoid missing signiﬁcant lesions. Nevertheless,
further studies on validation and training requirements
are necessary.
In conclusion, this feasibility study shows that CE offers
a safe and effective method in triaging patients presenting
with symptoms of UGIB who do not require hospital
admission. This may potentially relieve the burden on
hospital admissions.
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